1 completed, 1 terminated. 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Completed 1 |
| Phase 3 | 1 | Terminated 1 |
Follow GAD: new trials by email Literature Review of GAD trials Research Report on GAD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Research Exploring Sleep Education & Technology Specialized sleep-related message interventions, GAD - Sleep Health | Not applicable | Completed | NYU Langone Health | 1060 | 2019-02-01 | 2020-01-30 |
| A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (EU) rhGAD65, Placebo - Type 1 Diabetes Mellitus | Phase 3 | Terminated | Diamyd Therapeutics AB | 334 | 2008-07-01 | 2011-10-10 |
Diabetes Mellitus (1) · Diabetes Mellitus, Type 1 (1)
Diamyd Therapeutics AB (1) · NYU Langone Health (1)
Finland (1) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · Slovenia (1) · Spain (1) · Sweden (1) · United Kingdom (1) · United States (1)
Girardin Jean-Louis, MD (1) · Johnny Ludvigsson, MD, PhD (1)